AOA Dx

Co-founder and Chief Regulatory Officer leading development of the GlycoLocate platform, with experience in FDA submissions (510(k), PMA, CLIA) and launching diagnostics globally. She was named to Inc.'s 2022 Female Founders 100 List.

Co-founder and CEO of AOA Dx, a leader in women's health and diagnostics recognized in Inc's 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis. She holds a degree in Economics and International Relations from Boston University.

CSO with nearly two decades leading oncology-focused R&D teams across research, regulatory submission and product launches. She earned her PhD at Northeastern University and completed postdoctoral fellowships at the University of Arizona.

Bioanalytical and proteomics expert with over 25 years advancing mass spectrometry-based diagnostics, with prior roles at Quest Diagnostics, Cleveland HeartLab, Ultragenyx and Cedars-Sinai. He holds a PhD from the University of Oregon.

Drew Watson works in biostatistics, machine learning, and personalized medicine. He founded Nephrosant, a molecular diagnostics company focused on kidney health, and advises companies in personalized medicine, diagnostics, and pharmaceutical development. His earlier oncology work included contributing to the development of Oncotype DX for breast cancer and diagnostic tests for several other cancers. Before entering diagnostics, he advised international companies on quality management under Dr. W. Edwards Deming. He holds a BS in Statistics from California State University East Bay, an MS in Statistical Computing from Stanford University, a PhD in Biostatistics from UCLA, and an MBA from Golden Gate University.

Clinical operations executive with over 15 years leading global clinical programs across biotech, diagnostics and medical devices. She holds degrees from Saint Louis University plus PMP and CCRP certifications.

Diagnostics development leader with over 12 years in IVD assay development and design control, with prior roles at Thermo Fisher, PGDx, Precision for Medicine and Exact Sciences. She holds degrees from the University of Pennsylvania and MIT.

Computational biologist and biostatistician with expertise in genomics and microbiome science, founder of Resphera Biosciences. He holds a PhD in Applied Mathematics from the University of Maryland.

Founding and Managing Partner of Easton Capital Investment Group with roughly 20 years of investing experience and prior roles at Warburg Pincus and Security Pacific Capital Investors. He holds degrees from Yale College and Yale Law School.

Board-certified Gynecologic Oncologist and Assistant Clinical Professor at UT Health San Antonio, with expertise in advanced pelvic surgery and research into cost-effectiveness and financial toxicity in cancer care.

Physician-scientist and practicing gynecologic oncologist at Cleveland Clinic focused on translational medicine and early cancer detection, with training from Harvard, Vanderbilt, Brigham and Women's Hospital, Dana-Farber and MIT.

Pioneer in lipidomics with over two decades in academia, biotech and regulatory science, founder of Lipidomics Consulting Ltd. and President of the International Lipidomics Society. He earned his PhD from the Technical University of Dresden.

Founder and former CEO of nVision Medical (acquired by Boston Scientific in 2018 for $275M) and Y Combinator's first healthcare and biotech partner, she sits on multiple boards.

World-leading translational medicine scientist with over 200 publications and 21 patents, focused on targeting gangliosides for cancer diagnosis and therapy. He is based at McGill University and the Lady Davis Institute in Montreal.

Diagnostics R&D leader with experience at Ventana Medical Systems (Roche), Personal Genome Diagnostics and Exact Sciences. He leads AOA's R&D team advancing LC-MS and immunoassay technologies and holds degrees from Arizona State University and the University of Arizona.